Stay updated with breaking news from Crizotinib Combination. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting...
/PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and...
Item 8.01 Other Events Clinical Updates On April 23, 2023, IDEAYA Biosciences, Inc. announced interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib synthetic... | June 18, 2023
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ... | June 18, 2023
Confirmed overall response rate of 45%, disease control rate of 90% and median PFS of ~7 months in 20 evaluable First-Line MUM patientsBased on FDA meeting, initiating Phase 2/3 registrational... | April 23, 2023